Skip to content

Study · Non-randomized trial · n = 437 · 2016

5 results

Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.

Yabe D, Ambos A, Cariou B, Duvnjak L, Evans M, González-Gálvez G, Lin J, Nikonova EV, de Pablos-Velasco P, Yale JF, Ahrén B

Journal of diabetes and its complications24 May 2016Cited by 16 (Europe PMC)

PMID27267268 (opens in a new tab)DOI10.1016/j.jdiacomp.2016.05.018 (opens in a new tab)PepBankPUB-27267268
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, HbA1c changes across SUIT quartiles were -0.99, -0.87, -0.86 and -0.83% (-10.8, -9.5, -9.4 and -9.1 mmol/mol).

    In plain wordsIn patients with diabetes, HbA1c decreased from baseline in every beta-cell function quartile during lixisenatide treatment.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c at week 24 by SUIT quartile
    Study

    n = 437

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20μg once dailyAs given in this study (human).

    Measurements

    HbA1c change from baseline at week 24
    −0.99%
    Quartile 1
    HbA1c change from baseline at week 24
    −0.87%
    Quartile 2
    HbA1c change from baseline at week 24
    −0.86%
    Quartile 3
    HbA1c change from baseline at week 24
    −0.83%
    Quartile 4
    HbA1c change from baseline at week 24
    −10.8 mmol/mol
    Quartile 1
    HbA1c change from baseline at week 24
    −9.5 mmol/mol
    Quartile 2
    HbA1c change from baseline at week 24
    −9.4 mmol/mol
    Quartile 3
    HbA1c change from baseline at week 24
    −9.1 mmol/mol
    Quartile 4

    Source sentences

    Summary
    Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect P<0.0001).
    1 context sentence
    Summary · context
    In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, postprandial glucose changes across SUIT quartiles were -7.9, -5.6, -5.5 and -4.3 mmol/L (overall effect P<0.0001).

    In plain wordsIn patients with diabetes, postmeal glucose decreased from baseline in every beta-cell function quartile during lixisenatide treatment.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glucose at week 24 by SUIT quartile
    Study

    n = 437

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20μg once dailyAs given in this study (human).

    Measurements

    Postprandial plasma glucose change from baseline at week 24
    −7.9 mmol/L
    Quartile 1
    Postprandial plasma glucose change from baseline at week 24
    −5.6 mmol/L
    Quartile 2
    Postprandial plasma glucose change from baseline at week 24
    −5.5 mmol/L
    Quartile 3
    Postprandial plasma glucose change from baseline at week 24
    −4.3 mmol/L
    Quartile 4

    Source sentences

    Summary
    Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect P<0.0001).
    1 context sentence
    Summary · context
    In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide reduced postprandial glucagon from baseline in all SUIT quartiles.

    In plain wordsIn patients with diabetes, postmeal glucagon decreased from baseline in all beta-cell function quartiles during lixisenatide treatment.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glucagon
    Study

    n = 437

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20μg once dailyAs given in this study (human).

    Source sentences

    Summary
    Furthermore, postprandial glucagon was reduced in all SUIT quartiles, while insulinogenic index improved only in patients with higher baseline SUIT (overall effect P=0.0286).
    1 context sentence
    Summary · context
    In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, insulinogenic index improved only with higher baseline SUIT during lixisenatide treatment (overall effect P=0.0286).

    In plain wordsIn patients with diabetes, insulinogenic index improved from baseline only in higher beta-cell function groups during lixisenatide treatment.

    Peptide
    Lixisenatide
    Outcome
    MixedInsulinogenic index
    Study

    n = 437

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20μg once dailyAs given in this study (human).

    Source sentences

    Summary
    Furthermore, postprandial glucagon was reduced in all SUIT quartiles, while insulinogenic index improved only in patients with higher baseline SUIT (overall effect P=0.0286).
    1 context sentence
    Summary · context
    In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index.
  5. 05HumanNon-randomized trialSafety outcome

    In patients with type 2 diabetes receiving lixisenatide, no severe symptomatic hypoglycemic events were reported.

    In plain wordsIn patients with diabetes receiving lixisenatide, no severe symptomatic hypoglycemic events were reported.

    Peptide
    Lixisenatide
    Outcome
    Not applicableSevere symptomatic hypoglycemic events
    Study

    n = 437

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    20μg once dailyAs given in this study (human).

    Source sentences

    Summary
    No severe symptomatic hypoglycemic events were reported.
    1 context sentence
    Summary · context
    In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00713830

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

Sanofin = 859Jul 2008 to Jan 2011

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 14 Dec 2016
CompletedPhase 3Results postedNCT00712673

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Sanofin = 680Jun 2008 to Mar 2011

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 15 Dec 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.